Once-weekly insulin efsitora alfa shows promising results in adults starting insulin
Eli Lilly and Company (NYSE: LLY) reported encouraging data from its QWINT-2 study, testing once-weekly insulin efsitora alfa in adults who were new to insulin therapy for type 2 diabetes. In head-to-head comparisons, efsitora delivered A1C reductions on par with commonly used once-daily insulins, pointing to a simpler dosing option without giving up glucose control.
Study overview
QWINT-2 is a phase 3 trial that compared efsitora with once-daily insulin degludec in insulin-naïve adults. The results were published in a peer-reviewed medical journal and presented at a major diabetes conference. Efsitora reduced A1C by 1.34%, stacking up closely against insulin degludec, which reduced A1C by 1.26%.
Trial results and impact
After 52 weeks, the average A1C reached 6.87% for participants on efsitora and 6.95% for those on insulin degludec. Beyond A1C, participants using efsitora gained an extra 45 minutes per day in the target glucose range, and they did so without an increase in hypoglycemic events. Weekly dosing with stable glucose control—and without added low blood sugar—suggests efsitora could make day-to-day management a little easier.
Expert insights
Clinicians often emphasize that simpler regimens help people stick with treatment. Dr. Carol Wysham of the University of Washington noted the potential shift from daily to weekly insulin and its practical upside, saying that moving to a weekly option may ease the treatment burden and support adherence while keeping A1C in check.
Safety profile and comparisons
Across safety measures, efsitora’s profile was comparable to standard daily insulins. Severe hypoglycemia occurred less often with efsitora than with degludec, and no severe events were reported among participants receiving efsitora in the trial. Taken together, these findings support efsitora as a potentially dependable choice for appropriate patients.
Conclusion and future perspectives
Weekly insulin that maintains control could be a meaningful step for people balancing diabetes care with everyday life. As the clinical program continues to broaden globally, Eli Lilly’s work centers on options that aim to simplify how people manage diabetes while preserving outcomes that matter—A1C, time in range, and safety.
About the QWINT clinical trial program
The QWINT program for efsitora includes multiple global studies enrolling people with both type 1 and type 2 diabetes. Launched in 2022, it is designed to generate robust evidence on once-weekly insulin across diverse populations and care settings, with a goal of informing real-world accessibility to modern diabetes care.
About insulin efsitora alfa
Efsitora alfa is a basal insulin engineered for once-weekly dosing. Its design aims to maintain more stable glucose levels and reduce day-to-day variability, offering another approach to long-acting insulin therapy.
About Eli Lilly and Company
Eli Lilly and Company develops medicines intended to improve health worldwide. With a history spanning more than 150 years, the company continues to advance treatments across major conditions, including diabetes, and to explore ways to make care more manageable for the people who need it.
Frequently Asked Questions
What is insulin efsitora alfa?
It’s a once-weekly basal insulin designed to help adults with type 2 diabetes manage blood sugar, with a focus on steady glucose control and less day-to-day variability.
What did the QWINT-2 trial find?
Efsitora reduced A1C by 1.34%, similar to insulin degludec’s 1.26% reduction. At 52 weeks, average A1C was 6.87% with efsitora and 6.95% with degludec. Participants on efsitora also spent about 45 more minutes per day in the target glucose range, without an increase in hypoglycemia.
How did safety compare with daily insulin?
Efsitora’s overall safety profile was comparable to daily insulins in the study. Severe hypoglycemia occurred less often with efsitora, and no severe events were reported among participants who received it.
Who took part in QWINT-2?
The trial enrolled adults with type 2 diabetes who had not previously used insulin (insulin-naïve) and compared once-weekly efsitora with once-daily insulin degludec. Findings were published in a medical journal and presented at a major diabetes meeting.
What is the broader QWINT program?
QWINT is a global series of studies, begun in 2022, evaluating once-weekly insulin efsitora in people with type 1 and type 2 diabetes. The aim is to build a clear picture of effectiveness, safety, and usability across different populations.
